Atypical antidopaminergic properties of CI-686: a potential antipsychotic agent.
The effects of the antipsychotic/antidepressant drug CI-686 on apomorphine- and amphetamine-induced stereotypies, dopamine metabolism, neuroleptic binding, and serum prolactin levels were determined. CI-686 displayed profiles of activity in each of these systems that differs markedly from those of other antipsychotics. CI-686's unique preclinical profile suggests a mechanism of action other than dopamine antagonism which could have implications regarding current thinking on the pathophysiology of schizophrenia.
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology*; D001667:Binding, Competitive; D002839:Chromans / Q000494:pharmacology*; D018492:Dopamine Antagonists; D006801:Humans; D008297:Male; D011388:Prolactin / Q000097:blood; D011869:Radioligand Assay; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects
D014150:Antipsychotic Agents; D001578:Benzopyrans; D002839:Chromans; D018492:Dopamine Antagonists; D011388:Prolactin; D000661:Amphetamine; C006122:trebenzomine; D001058:Apomorphine